This vial combines CJC-1295 without Drug Affinity Complex (a modified GHRH analog, also described as Mod GRF 1-29) with ipamorelin, a selective ghrelin-receptor (GHS-R1a) ligand. Laboratories use the pair to study complementary GHRH-receptor and ghrelin-receptor signaling.
This listing is for laboratory research only. It is not a medicine and this page does not provide dosing or administration guidance. Photography and lot documentation are still being prepared, so the vial cannot be purchased yet.
Laboratory specifications
| Catalog name | CJC-1295 No DAC + Ipamorelin |
|---|---|
| Type | Two-component lyophilized research blend |
| Components | CJC-1295 without DAC (modified GHRH analog) and ipamorelin |
| Available amount | 10 mg vial (combined mass as labeled) |
| Form | Lyophilized powder |
| Intended use | Laboratory research only |
| Lyophilized storage | Keep frozen, desiccated, and protected from light until use |
| After reconstitution | Typical research handling is 2–8°C, about 30 days, no repeated freeze–thaw cycles |
Component masses will be printed on the vial label and in lot documentation when this listing is released.
Match any published report to the lot printed on the vial before bench use. Product photos are not a substitute for lot-specific documentation.
